Investment Rating - The investment rating for the company is "Buy" (maintained) with a target price of 22.36 CNY [1]. Core Views - The company has achieved rapid growth in performance, with innovative pipelines continuing to deliver results. The first innovative product has been approved for market, marking 2025 as a year of commercialization [4][8]. - The company has successfully transformed through innovation, with significant sales growth driven by new product launches and effective cost control [8]. - The financial forecast has been slightly adjusted due to increased sales expenses from new drug launches, with projected net profits for 2025 and 2026 being 215 million CNY and 312 million CNY respectively [5]. Financial Performance Summary - The company reported a revenue of 1,778 million CNY in 2024, a year-on-year increase of 23.15%, and a net profit of 160 million CNY, up 207.92% [8]. - For 2025, the expected revenue is 2,021 million CNY, reflecting a growth of 13.7%, with a projected net profit of 215 million CNY, a growth of 34.2% [7]. - The gross margin is expected to remain stable around 80.5% to 81.0% over the forecast period [7]. Valuation Summary - The absolute valuation predicts a reasonable market value of 20.76 billion CNY, corresponding to a target price of 22.36 CNY per share [5][10]. - The company's financial ratios indicate a projected price-to-earnings ratio (P/E) decreasing from -110.6 in 2023 to 34.8 in 2027, reflecting improving profitability [7].

证券代码：002755 证券简称：奥赛康 公告编号：2025-034 北京奥赛康药业股份有限公司 持股 5%以上股东减持计划期限届满 暨股份变动触及 1%的公告 持股 5%以上的股东中亿伟业控股有限公司保证向本公司提供的 信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 | | | 本次减持前持有股份 | | 本次减持后持有股份 | | | --- | --- | --- | --- | --- | --- | | 股东 | 股份性质 | 股数 | 占总股本 | 股数 | 占总股本 | | 名称 | | | 比例 | | 比例 | | | | （股） | | （股） | | | | | | （%） | | （%） | | | 合计持有股份 | 134,113,436 | 14.45% | 120,192,033 | 12.95% | | 中亿伟业控股 有限公司 | 其中： | 134,113,436 | 14.45% | 120,192,033 | 12.95% | | | 无限售条件股份 | | | | | | | 有限售条件股份 | 0 | 0 | 0 | 0 | （二） 其他相关说明 北京 ...

证券代码：002755 证券简称：奥赛康 公告编号：2025-033 暨实施结果的公告 持股 5%以上的股东江苏苏洋投资实业有限公司保证向本公司提 供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 北京奥赛康药业股份有限公司（以下简称"公司"）于 2025 年 1 月 9 日披露 了《关于持股 5%以上股东减持计划的预披露公告》（公告编号：2025-002），公 司股东江苏苏洋投资实业有限公司（以下简称"苏洋投资"）计划于 2025 年 2 月 7 日至 2025 年 5 月 6 日以集中竞价和大宗交易方式减持本公司股份不超过 13,922,400 股，不超过本公司总股本的 1.50%。 2025 年 5 月 6 日，公司收到苏洋投资出具的《股份减持计划期限届满的告 知函》，截至 2025 年 5 月 6 日，苏洋投资本次减持计划已期限届满，通过集中竞 价和大宗交易方式累计减持本公司股份 13,922,285 股，占本公司总股本的 1.50%。 本次股份变动后，苏洋投资持有本公司股份 124,415,362 股，占本公司 ...

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [8][29]. Core Insights - The industry is experiencing a return to normal growth, with a notable performance in chemical pharmaceuticals, while the overall revenue growth for 2024 is projected to decline by 0.6% year-on-year, marking the first decline in recent years [12][14]. - The report highlights a significant disparity among sectors, with chemical pharmaceuticals showing a remarkable net profit growth of 97.7%, while biological products face substantial short-term performance pressure [17][18]. - The current low allocation and valuation levels present a high cost-performance ratio for investments in the pharmaceutical sector, suggesting it is an excellent time to allocate resources [19][28]. Summary by Sections 1. Innovation in the Pharmaceutical Chain - The report notes that the impact of national procurement and anti-corruption measures is gradually diminishing, leading to a normal release of rigid demand in hospitals [11]. - The overall revenue growth for the industry in 2024 is projected at -0.6%, with net profit and non-recurring net profit declining by 8.1% and 5.9% respectively [12][13]. 2. Investment Recommendations - The report suggests focusing on the innovation drug supply chain (Biotech + CXO + upstream) and certain overseas medical devices, recommending companies such as Aosaikang, Yifang Bio, and WuXi AppTec for investment [29]. - For in-hospital products (traditional Chinese medicine, chemical pharmaceuticals, and medical devices), companies like Hengrui Medicine and Mindray Medical are highlighted as having more certain growth prospects [29]. 3. Market Positioning - The report indicates that the allocation of public fund products in pharmaceutical stocks has decreased from 11.2% in Q1 2024 to 8.7% in Q4 2024, with a slight recovery to 9.1% by Q1 2025 [19][21]. - The pharmaceutical sector's price-to-earnings ratio is at a 10-year low, suggesting potential for growth as innovative products continue to emerge [22][24].

Market Performance - On May 6, the Shanghai Composite Index rose by 1.13%, the Shenzhen Component Index increased by 1.84%, and the ChiNext Index gained 1.97% [2] - A total of 59 stocks appeared on the "Dragon and Tiger List" due to significant price movements, with the highest net inflow of funds recorded for Yanshan Technology (002195.SZ) at 214 million yuan [2][3] Stock Highlights - Yanshan Technology saw a net purchase of 214 million yuan, accounting for 8.26% of the total trading volume, and closed with a 10.1% increase and a turnover rate of 8.41% [3][5] - The stock with the highest net outflow was Changshan Beiming (000158.SZ), which experienced a net sell of 148 million yuan, representing 2.37% of the total trading volume, and closed up by 10.02% with a turnover rate of 16.36% [3][6] Institutional Activity - Institutions were active in 27 stocks on the Dragon and Tiger List, with a total net purchase of 428 million yuan, buying 11 stocks and selling 16 [7] - The stock with the highest institutional net purchase was Qingdao Kingking (002094.SZ), which closed up by 9.97% and had a turnover rate of 19.6% [7] Northbound Capital - Northbound funds participated in 11 stocks on the Dragon and Tiger List, with a total net purchase of 216 million yuan, including a net buy of 83.6 million yuan for Yanshan Technology [12] - The stock with the highest net sell from northbound funds was Changshan Beiming, with a net sell of 29.4 million yuan [12] Summary of Key Stocks - Yanshan Technology: Net buy of 409.7 million yuan from institutions and 836.2 million yuan from northbound funds, with a total net buy of 1.2458 billion yuan [16] - Changshan Beiming: Net sell of 39.37 million yuan from institutions and 29.38 million yuan from northbound funds, totaling a net sell of 68.75 million yuan [16]

奥赛康今日下跌5.80%，全天换手率1.45%，成交额2.40亿元，振幅6.82%。龙虎榜数据显示，机构净卖 出1773.60万元，深股通净买入644.63万元，营业部席位合计净卖出1043.33万元。 深交所公开信息显示，当日该股因日跌幅偏离值达-8.05%上榜，机构专用席位净卖出1773.60万元，深 股通净买入644.63万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交1.18亿元，其中，买入成交额为4795.57 万元，卖出成交额为6967.88万元，合计净卖出2172.31万元。 具体来看，今日上榜的营业部中，共有7家机构专用席位现身，即买二、买三、买四、买五、卖二、卖 四、卖五，合计买入金额2274.61万元，卖出金额4048.22万元，合计净卖出1773.60万元，深股通为第一 大买入营业部及第一大卖出营业部，买入金额为2513.62万元，卖出金额为1868.99万元，合计净买入 644.63万元。 资金流向方面，今日该股主力资金净流出345.36万元，其中，特大单净流入287.59万元，大单资金净流 出632.94万元。近5日主力资金净流出205.18万元。（数据宝） 奥赛康5 ...

Core Viewpoint - The approval of Liratinib tablets for first-line treatment marks a significant breakthrough for the company in the field of targeted therapy for lung cancer, expanding its innovative drug strategy [1][2][8] Company Developments - The company’s subsidiary, Jiangsu Aosaikang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for Liratinib tablets, which are indicated for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations [1][2] - Liratinib is a third-generation EGFR TKI developed collaboratively with the Chinese Academy of Sciences, featuring independent intellectual property rights and significant efficacy [1][2] Clinical Data and Efficacy - Clinical trials for Liratinib showed an objective response rate (ORR) of 68.8% and a disease control rate (DCR) of 92.4%, with a median duration of response (DoR) of 11.1 months and a median progression-free survival (PFS) of 11.0 months [4] - The drug demonstrated good efficacy in patients with central nervous system (CNS) metastases, with an ORR of 65.9% and a median PFS of 10.6 months [4] Market Potential and Commercialization - The domestic EGFR TKI market exceeds 20 billion yuan, and with the exclusive commercialization partnership with Innovent Biologics, Liratinib is expected to accelerate market penetration due to its efficacy and pricing advantages [5] - The company reported a net profit of 160 million yuan in 2024, indicating a turnaround and potential for stock price recovery and value reassessment [5] Research and Development Focus - The company has a robust pipeline with 42 ongoing projects, including 10 key innovative drugs in clinical research, and continues to invest heavily in R&D, with 354 million yuan allocated in 2024 [6][7] - The company aims to enhance its competitive edge by focusing on the development of small molecule targeted innovative drugs and tumor immunobiological innovative drugs [7][8]

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a long-term focus on domestic innovative drugs in the oncology field and AI medical investment opportunities [3][4]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.16%, outperforming the Wind All A index (1.15%) and the CSI 300 index (0.38%) [3][8]. - The upcoming ASCO conference is highlighted as a significant event for domestic innovative drug companies, with over 70 oral presentations and more than 10 major studies expected [3][4]. - The Ministry of Industry and Information Technology and six other departments issued a plan for the digital transformation of the pharmaceutical industry, aiming for significant advancements by 2027 and full coverage by 2030 [3][4]. Market Weekly Review - The pharmaceutical and biotechnology sector increased by 1.16% from April 21 to April 25, outperforming the Wind All A index and the CSI 300 index [3][8]. - Notable performers included medical research outsourcing (6.34%) and raw materials (4.72%), while blood products (-3.26%) and vaccines (-6.38%) continued to decline [3][9]. - Individual stock performances showed significant gains for Yong'an Pharmaceutical (31.4%), Shuyou Shen (28.4%), and Erkang Pharmaceutical (27.7%), while *ST Jiyuan (-43.2%), Nanhua Biological (-35.3%), and Shuangcheng Pharmaceutical (-27.7%) faced substantial losses [3][11]. Industry News and Key Company Announcements - On April 25, Kangfang Bio announced FDA approval for its drug Anike for the treatment of recurrent or metastatic nasopharyngeal carcinoma [12]. - The same day, Kangfang Bio also reported the approval of its PD-1/VEGF bispecific antibody for first-line treatment of specific lung cancer types [13]. - The digital transformation plan for the pharmaceutical industry aims to enhance competitiveness and quality management through AI and data integration by 2030 [3][4].

Regulatory Developments - The National Health Commission and other departments have released the 2025 National Random Supervision and Inspection Plan, which includes new regulatory areas such as internet diagnosis and treatment, and mental health, while explicitly targeting online medical fraud [1] - The regulatory focus on combating online medical fraud represents a significant upgrade in medical supervision, aiming to purify the medical online space [1] Pharmaceutical Approvals - Innovent Biologics announced that its third-generation EGFR TKI drug, Olitinib (Leratinib), has received approval from the National Medical Products Administration (NMPA) for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations [2] - Olitinib is the only approved third-generation EGFR TKI based on a naphthalene structure, expanding treatment options for EGFR mutation-positive NSCLC patients [2] Market Regulation and Antitrust Issues - Xianju Pharmaceutical is facing a potential fine of approximately 195 million yuan for alleged monopolistic practices related to the pricing of dexamethasone phosphate raw materials, with the case still under review by the Tianjin Market Supervision Administration [3] - This incident highlights the regulatory authorities' emphasis on antitrust measures within the pharmaceutical industry, which could disrupt normal market operations [3] Combination Therapy Approvals - Pfizer announced that its oral targeted drug, Axi-cabtagene ciloleucel (Axitinib), has been approved for first-line treatment in combination with Toripalimab for high-risk, unresectable, or metastatic renal cell carcinoma (RCC) patients [4] - This approval marks the first and only approved first-line targeted and immune combination therapy for advanced kidney cancer in China, indicating a shift towards combination therapies in the treatment landscape [4]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002755 证券简称：奥赛康 公告编号：2025-031 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第一季度报告是否经审计 将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界 定为经常性损益项目的情况说明 □是 R否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 R否 （二） 非经常性损益项目和金额 R适用 □不适用 单位：元 其他符合非经常性损益定义的损益项目的具体情况 □适用 R不适用 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 □适用 R不适用 公司不存在将《公开发行证券的公司信息披露解释性公告第1号—— ...